article thumbnail

Subcutaneous Medications and Drug Delivery Systems

Roots Analysis

Given the robust pipeline of biologics, which include monoclonal antibodies, vaccines and other protein-based therapeutic products, subcutaneous medications are being investigated for various clinical candidates across different phases of development.

article thumbnail

Next week: Accelerate development of advanced biotherapeutics

Drug Discovery World

Biophysical data combined with functional assays are needed to predict efficacy and potency, optimise drug delivery, assess critical quality attributes, and improve biologics drug design. Characterizing binding properties of complex biomolecules is a critical step.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Exclusive event: Accelerate the development of advanced biotherapeutics

Drug Discovery World

Biophysical data combined with functional assays are needed to predict efficacy and potency, optimise drug delivery, assess critical quality attributes, and improve biologics drug design. Characterizing binding properties of complex biomolecules is a critical step.

article thumbnail

Turning science into business: An optimised alternative to antibodies

Drug Discovery World

I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development. What advantages do they offer over antibodies?   DS: How are aptamers currently used in the development of precision treatments?

article thumbnail

Subcutaneous Biologics: The Unmet Requirement in the Pharmaceutical Space

Roots Analysis

However, several drug delivery devices that enable patients to self-administer their respective medications are now available. Subcutaneous drug delivery systems – the helping hand for patients. The emergence of safer and patient-friendly devices is acting as a strong enabler for subcutaneous delivery of therapeutics.

article thumbnail

Boehringer buys Abexxa, bolstering its immuno-oncology pipeline

pharmaphorum

Texas-based Abexxa has been on the Boehringer’s radar since it was set up, as it provided seed funding for the preclinical-stage company in 2016, buying into its approach of developing antibodies against targets inside cancer cells, rather than on the cell membrane. Last December, Boehringer paid €1.8

article thumbnail

JS Bio and Etta Biotech Advancing Strategic Partnership

The Pharma Data

Etta Biotech”), to set up a high titer transient protein expression platform for high quality protein production using JS Bio’s transient transfection media. JS Bio becomes the exclusive cell culture supplier for Etta Biotech’s transient transfection high titer protein expression platform. JS Bio’s parent company.

Protein 52